Polymeric Nanoparticles for Inhaled Vaccines

Al-Nemrawi, Nusaiba K.; Darweesh, Ruba S.; Al-shriem, Lubna A.; Al-Qawasmi, Farah S.; Emran, Sereen O.; Khafajah, Areej S.; Abu-Dalo, Muna A.

doi:10.3390/polym14204450

Cited by 10 publications

(6 citation statements)

References 226 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The term "polymeric nanoparticle" refers to solid nanospheres or nanocapsules that either adsorb molecules on their surface or encapsulate them within a polymeric matrix as shown in Figure 2 [19,23,24]. Biodegradable polymeric nanoparticles are the most promising drug delivery strategy for pulmonary/respiratory applications [25,26]. PNPs can be used instead of liposomes.…”

Section: Polymer Nanoparticles (Pnps)mentioning

confidence: 99%

Polymeric Nanoparticles (PNPs) as drug delivery systems for SARS-CoV-2

Adu,

Patel,

Catino

et al. 2024

Charact. Appl. Nanomater.

View full text Add to dashboard Cite

Researchers from all over the world have been working tirelessly to combat the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) COVID-19 pandemic since the World Health Organization (WHO) proclaimed it to be a pandemic in 2019. Expanding testing capacities, creating efficient medications, and creating safe and efficient COVID-19 (SARS CoV-2) vaccinations that provide the human body with long-lasting protection are a few tactics that need to be investigated. In clinical studies, drug delivery techniques including nanoparticles have been used since the early 1990s. Since then, as technology has advanced and the need for improved medication delivery has increased, wherein the field of nanomedicine has recently seen significant development. PNPs, or polymeric nanoparticles, are solid particles or particulate dispersions that range in size from 10 to 1000 nm and their ability to efficiently deliver therapeutics to specific targets makes them ideal drug carriers. This review article discusses the many polymeric nanoparticle (PNP) platforms developed to counteract the recent COVID-19 pandemic-related severe acute respiratory syndrome coronavirus (SARS-CoV-2). The primary subjects of this article are the size, shape, cytotoxicity, and release mechanism of each nanoparticle. The two kinds of preparation methods in the synthesis of polymeric nanoparticles have been discussed: the first group uses premade polymers, while the other group depends on the direct polymerization of monomers. A few of the PNPs that have been utilized to combat previous viral outbreaks against SARS-CoV-2 are also covered.

show abstract

Section: Polymer Nanoparticles (Pnps)mentioning

confidence: 99%

Polymeric Nanoparticles (PNPs) as drug delivery systems for SARS-CoV-2

Adu,

Patel,

Catino

et al. 2024

Charact. Appl. Nanomater.

View full text Add to dashboard Cite

show abstract

“…Using an electronic atomizer like the ViaNaseTM, a nasal spray can be directed directly at the respiratory epithelia lining the nasal canal and the olfactory region [107,108]. Humans use ViaNaseTM to administer insulin intranasally [109]. The device comprises of a hermetically sealed nosepiece and a mechanism that generates an active vortex of nebulized particles.…”

Section: Device For Nose To Brain Deliverymentioning

confidence: 99%

Recent Advancement in Self Emulsifing Drug Delivery System

Bist

Faruk

2023

J. Res. Appl. Sci. Biotechnol.

View full text Add to dashboard Cite

Every day, researchers make new attempts to identify neurotherapeutics, but few of them make it to clinical trials. The main cause is their low bioavailability, which is connected to low water solubility, low permeability through biological membranes, and the hepatic first-pass metabolism. However, the most significant challenge in administering drugs to the brain is overcoming the blood-brain barrier. In order to get around it, intranasal administration has become more popular, sometimes even more so than oral administration. Because of its structure, the nasal cavity can bypass the blood-brain barrier and transport drugs to the brain directly. Nasal absorption increases the systemic bioavailability of highly processed substances because they bypass the hepatic first-pass metabolism. However, due to their unique physicochemical properties, most neurotherapeutics must be synthesized in lipidic nanosystems as self-emulsifying drug delivery systems (SEDDS). To load large quantities of lipophilic medicines into micro or nanoemulsions, these isotropic mixes of oils, surfactants, and co-surfactants are diluted in water. The goal of SEDDS is to increase the stability of labile pharmaceuticals against enzymatic activity, boost drug penetration through absorptive membranes, and reduce the likelihood of drug precipitation at absorption sites. Therefore, improved brain targeting and bioavailability of medications might be anticipated by combining the benefits of SEDDS with those of the intranasal route for brain delivery. In order to better understand the mechanisms involved in the intranasal administration of pharmaceuticals loaded in SEDDS, this paper provides a comprehensive characterization of SEDDS as a lipidic nanosystem. Finally, the in vivo effects of intranasal or oral delivery of SEDDS, showing their superiority over standard solutions or suspensions, are described.

show abstract

“…Inhaled nanoformulations initially come into contact with MPs and DCs in the lower respiratory tract, resulting in nanoformulations with smaller size, and are best taken up by MPs, whilst larger one are phagocytosed by DCs [152]. The phagocytosis mechanisms Pulmonary surfactant (PS), an amphiphilic lipoprotein complex, is secreted by alveolar type II (AT-II) cells in the pulmonary epithelium.…”

Section: Biological Barriers To Delivery Of Anti-tb Drugsmentioning

confidence: 99%

Nanocarriers in Tuberculosis Treatment: Challenges and Delivery Strategies

Kumar,

Virmani,

Kumar

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

The World Health Organization identifies tuberculosis (TB), caused by Mycobacterium tuberculosis, as a leading infectious killer. Although conventional treatments for TB exist, they come with challenges such as a heavy pill regimen, prolonged treatment duration, and a strict schedule, leading to multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains. The rise of MDR strains endangers future TB control. Despite these concerns, the hunt for an efficient treatment continues. One breakthrough has been the use of nanotechnology in medicines, presenting a novel approach for TB treatment. Nanocarriers, such as lipid nanoparticles, nanosuspensions, liposomes, and polymeric micelles, facilitate targeted delivery of anti-TB drugs. The benefits of nanocarriers include reduced drug doses, fewer side effects, improved drug solubility, better bioavailability, and improved patient compliance, speeding up recovery. Additionally, nanocarriers can be made even more targeted by linking them with ligands such as mannose or hyaluronic acid. This review explores these innovative TB treatments, including studies on nanocarriers containing anti-TB drugs and related patents.

show abstract

Polymeric Nanoparticles for Inhaled Vaccines

Cited by 10 publications

References 226 publications

Polymeric Nanoparticles (PNPs) as drug delivery systems for SARS-CoV-2

Polymeric Nanoparticles (PNPs) as drug delivery systems for SARS-CoV-2

Recent Advancement in Self Emulsifing Drug Delivery System

Nanocarriers in Tuberculosis Treatment: Challenges and Delivery Strategies

Contact Info

Product

Resources

About